VPTDF (VentriPoint Diagnostics) Research & Development: $0.27 Mil (TTM As of Dec. 2025)


VPTDF VentriPoint Diagnostics Ltd VPTDF
6 GF Score
Price $0.08
! 4 Warning Signs
View Full Analysis

What is VentriPoint Diagnostics Research & Development?

VentriPoint Diagnostics VPTDF 6 Research & Development is $0.27 Mil as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. VentriPoint Diagnostics's Research & Development for the three months ended in Dec. 2025 was $0.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.27 Mil.

VentriPoint Diagnostics  (OTCPK:VPTDF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

VentriPoint Diagnostics Research & Development Related Terms

VentriPoint Diagnostics Research & Development Historical Data

* Premium members only.

The historical data trend for VentriPoint Diagnostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VentriPoint Diagnostics Research & Development Chart

VentriPoint Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.77 0.81 0.68 0.27

VentriPoint Diagnostics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.08 0.06 0.07 0.07
VPTDF
6GF Score
VentriPoint Diagnostics Ltd VPTDF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VentriPoint Diagnostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.27 Mil mean?
VentriPoint Diagnostics (VPTDF) has a Research & Development of $0.27 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on VentriPoint Diagnostics and its competitors.
Is VentriPoint Diagnostics' Research & Development too high?
VentriPoint Diagnostics' current Research & Development is $0.27 Mil. Overall, VentriPoint Diagnostics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' Research & Development compare to ABT and SYK?
VentriPoint Diagnostics' Research & Development of $0.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current Research & Development is $0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Research & Development of $0.27 Mil. The current Research & Development is $0.27 Mil. VentriPoint Diagnostics' overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Research & Development is $0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
6GF Score

Get the complete analysis for VPTDF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price